Background Background The ongoing coronavirus disease-19 (COVID-19) pandemic, caused by the novel coronavirus 2 (SARS-CoV-2) has triggered a worldwide search for medications addressing the morbidity and mortality associated with it. Various medications have been proposed and applied to control COVID-19 based on previous experiences with other viral infections. Some of these have been shown to be harmful or lack efficacy. This review discusses the medications that have been repurposed for SARS-CoV-2, experimental medications undergoing clinical trials, as well as the regional variations in COVID-19 treatments. Methods Methods A literature search was conducted to cover the period of January 2020 to September 2020 using the keywords "medications, treatment, therapeutics, pharmacological management for COVID-19" in various combinations as search strings. PubMed, LitCOVID, Google Scholar, Science Direct, and clinicaltrials.gov were the databases utilized. Results Results Evidence from ongoing clinical trials has shown promise with antiviral medications such as remdesivir, as well as corticosteroids, and convalescent plasma for severe cases of COVID-19. There is still, however, some conflicting evidence on the true benefits of these treatments. Other medications such as interferons, monoclonal antibodies, immune modulators, do not have enough clinical evidence of their safety and efficacy in COVID-19 patients for their recommended use. The role of anticoagulants and pulmonary vasodilators is still being explored. The efficacy of hydroxychloroquine is yet to be demonstrated in COVID-19 patients and is currently no longer recommended. Experimental medications targeting specific viral proteases are future promising therapies. Conclusions Conclusions The retinue of medications being used to treat COVID-19 is evolving and expanding as more clinical trials provide results. Several potential medication therapies are currently being investigated. While awaiting an approved safe and efficacious medication to treat this virus, a periodic review of ongoing research is highly encouraged.

.Advanced glycation products' levels and mechanical properties of vaginal tissue in pregnancy.European Journal of Obstetrics and Gynecology and Reproductive Biology http://dx.doi.org/10. 1016/j.ejogrb.2017.04.037 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ABSTRACTObjectives: Non-enzymatic glycation is closely associated with altered mechanical properties of connective tissue. Pregnancy, marked with high levels of female hormones, confers unique alteration to the mechanical properties of pelvic connective tissues in order to meet their physiological demands.However, there are few studies on glycation content and its influence on the mechanical properties of pelvic connective tissues during pregnancy. We hypothesise that the glycation content in pelvic tissues will change with a corresponding change in their mechanical properties, and that these changes are influenced by hormone levels. This study aims to investigate the correlation of vaginal tissue glycation content and mechanical property changes during pregnancy in association with the expression of a key

No abstract

A few studies have revealed that the advanced glycation content of the vaginal wall in pelvic organ prolapse tissues is elevated. This elevation makes advanced glycation a significant association with the disease. Early detection of vaginal wall glycation could therefore be relevant in the prevention and management of pelvic organ prolapse. A vaginal wall biopsy to detect this would be ideal, but is invasive. Therefore the use of a more accessible organ to access, such as skin, would be beneficial. Our previous independent study suggests that conditions such as pregnancy, can induce a change in the vaginal tissues' glycation content. The aim of this study was to assess whether the skin glycation undergoes similar changes as observed in vaginal tissue glycation in the same subjects in order to prove the hypothesis that skin advanced glycation content can predict vaginal tissue glycation. A rat model was used. The vaginal tissues from non-pregnant and E15-E18 pregnant rats and skin tissues from the same rats were taken for the measurement of advanced glycation content. The glycation marker, pentosidine, was quantified by a high performance liquid chromatography. Our results demonstrated that glycation content in vaginal wall tissues from pregnant rats was lower than the tissues from non-pregnant ones, and a strong positive association between skin and vaginal wall pentosidine level was observed. We conclude that skin pentosidine is reflective of vaginal wall pentosidine. Skin glycation may therefore be a potential tool in the prediction and management of pelvic organ prolapse.